Oncocyte Q3 revenue $1.0M (down 52% QoQ), net loss $9.3M; engages Perella Weinburg for strategic alternatives

Insight Molecular Diagnostics Inc.

2023-Q3 EPS reported -$5.22 revenue$4,508,000

Total revenue $1.0M in Q3 2022 vs $2.1M prior quarter; net loss $9.3M ($0.08 per share) vs $13.8M loss ($0.15) in prior year.
DetermaRx sample volume up 51% YoY; onboards physician base +62% YoY.
Engaged Perella Weinburg Partners as advisor to evaluate strategic alternatives.
Cash, equivalents, and marketable securities $34.2M as of Sept 30, 2022.
DetermaIO sample volume from Early Adopters grew 117% QoQ.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Insight Molecular Diagnostics Inc. reported the three and nine months ended September 30, 2022 results: revenue $1.0 million, net income $9.3 million, EPS $0.08.

Period: the three and nine months ended September 30, 2022
Revenue: $1.0 million
Net income: $9.3 million
EPS: $0.08
Result: reported results

Exact text from the filing

from the past few years transition to market launches of several new high-value, reimbursed tests over coming quarters.” Third Quarter 2022 Financial Results Total revenue was $1.0 million for the third quarter of 2022, compared to $2.1 million for the prior quarter. Third quarter revenues associated with DetermaRx were $1.0 million, an increase of $0.1 million

View on SEC.gov

Browse all earnings releases →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031410

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.